Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib PK Study in Severe Renal Impairment
NCT07853131Phase 1Recruiting
- Sponsor
- Sanofi
- Start
- Sep 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of rilzabrutinib (2 arms), sponsored by Sanofi. Primary endpoint: Area Under the Curve at Day 2. Started Sep 2026; status: recruiting.
02
Drugs
rilzabrutinib
Beyond the preview
Go deeper on NCT07853131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07853131.